0QQO Stock Overview
Siegfried Holding AG, together with its subsidiaries, provides contract development and manufacturing of active pharmaceutical ingredients (API) and finished dosage forms to the pharmaceutical industry worldwide.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 3/6 |
| Past Performance | 2/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Siegfried Holding AG Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CHF873.00 |
| 52 Week High | CHF947.50 |
| 52 Week Low | CHF657.50 |
| Beta | 0.63 |
| 1 Month Change | -3.69% |
| 3 Month Change | 2.69% |
| 1 Year Change | 29.16% |
| 3 Year Change | 4.44% |
| 5 Year Change | 126.17% |
| Change since IPO | 534.98% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0QQO | GB Life Sciences | GB Market | |
|---|---|---|---|
| 7D | -1.6% | -9.8% | -0.7% |
| 1Y | 29.2% | -44.4% | -1.8% |
Return vs Industry: 0QQO exceeded the UK Life Sciences industry which returned -44.4% over the past year.
Return vs Market: 0QQO exceeded the UK Market which returned -1.8% over the past year.
Price Volatility
| 0QQO volatility | |
|---|---|
| 0QQO Average Weekly Movement | 3.7% |
| Life Sciences Industry Average Movement | 7.2% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in GB Market | 11.5% |
| 10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: 0QQO has not had significant price volatility in the past 3 months.
Volatility Over Time: 0QQO's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1873 | 3,945 | Wolfgang Wienand | www.siegfried.ch |
Siegfried Holding AG, together with its subsidiaries, provides contract development and manufacturing of active pharmaceutical ingredients (API) and finished dosage forms to the pharmaceutical industry worldwide. It offers pharmaceutical and analytical development, process and analytical transfer, commercial manufacturing and packaging, and scale-up and clinical trial material production services. The company develops and produces APIs and intermediates, as well as finished dosage forms, including solid oral dosage forms, sterile and aseptic filling injectables, ophthalmics, and inhalative products.
Siegfried Holding AG Fundamentals Summary
| 0QQO fundamental statistics | |
|---|---|
| Market cap | CHF3.81b |
| Earnings (TTM) | CHF112.69m |
| Revenue (TTM) | CHF1.27b |
33.8x
P/E Ratio3.0x
P/S RatioIs 0QQO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0QQO income statement (TTM) | |
|---|---|
| Revenue | CHF1.27b |
| Cost of Revenue | CHF951.09m |
| Gross Profit | CHF320.41m |
| Other Expenses | CHF207.72m |
| Earnings | CHF112.69m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | 26.27 |
| Gross Margin | 25.20% |
| Net Profit Margin | 8.86% |
| Debt/Equity Ratio | 53.1% |
How did 0QQO perform over the long term?
See historical performance and comparison